{"id":"palg-ratg","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Leukopenia"},{"rate":"5-10%","effect":"Anemia"},{"rate":"5-10%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"pALG (basiliximab) and rATG (thymoglobulin) are monoclonal antibodies that bind to and deplete T-cells, thereby reducing the immune response and preventing organ rejection in transplant patients.","oneSentence":"pALG and rATG are immunosuppressive drugs that work by inhibiting T-cell activation and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:28.146Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in kidney transplant patients"},{"name":"Prevention of organ rejection in heart transplant patients"}]},"trialDetails":[{"nctId":"NCT07345000","phase":"PHASE3","title":"A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-01","conditions":"Treatment-naïve Severe Aplastic Anemia","enrollment":210},{"nctId":"NCT07297550","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-15","conditions":"Severe Aplastic Anemia, Refractory Aplastic Anemia, Newly Diagnosed Aplastic Anemia","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"pALG/ rATG","genericName":"pALG/ rATG","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"pALG and rATG are immunosuppressive drugs that work by inhibiting T-cell activation and proliferation. Used for Prevention of organ rejection in kidney transplant patients, Prevention of organ rejection in heart transplant patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}